Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C
Open Access
- 1 October 2002
- journal article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 36 (4) , 1022
- https://doi.org/10.1053/jhep.2002.32679
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in ratsHepatology, 2001
- Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertensionGastroenterology, 2001
- Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosisGastroenterology, 2001
- Interleukin 10: the magic bullet for liver fibrosis?Gastroenterology, 2000
- Angiotensin II induces contraction and proliferation of human hepatic stellate cellsPublished by Elsevier ,2000
- Effect of Losartan, An Angiotensin Ii Receptor Antagonist, on Portal Pressure in CirrhosisHepatology, 1999
- Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy: association with regression of hepatic fibrosisJournal of Hepatology, 1999
- Therapy of hepatitis C: Other optionsHepatology, 1997
- A Multicenter Randomized Controlled Dose Study of Ursodeoxycholic Acid for Chronic Hepatitis CHepatology, 1994
- The N-Terminal Propeptide of Collagen Type III in Serum Reflects Activity and Degree of Fibrosis in Patients with Chronic Liver Disease†Hepatology, 1984